Orr, Shira
Huang, Ling
Moser, James
Stroopinsky, Dina
Gandarilla, Omar
DeCicco, Cori
Liegel, Jessica
Tacettin, Cansu
Ephraim, Adam
Cheloni, Giulia
Torres, Daniela
Kufe, Donald
Rosenblatt, Jacalyn
Hidalgo, Manuel
Muthuswamy, Senthil K.
Avigan, David
Funding for this research was provided by:
V Foundation for Cancer Research (Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”, Partially funded by The V Foundation. 2018 Translational Award Program (there is no specific number assigned to the award) Title: “Biomarkers for a Phase I/II Trial with anti-miR-155 in Diffuse Large B-cell Lymphoma”)
Article History
Received: 23 February 2022
Accepted: 4 June 2022
First Online: 14 July 2022
Declarations
:
: Funded in part by V Foundation.
: All animal studies were approved by BIDMC IACUC.